Lundbeck shares rose 3.2% after pre‑announcing Q1 revenue 7% above consensus, driven by Vyepti, Abilify and Trintellix.
Adjusted EBITDA exceeded forecasts by 23% thanks to higher gross margins, lower operating costs and a one‑time DKK470 million inventory contribution.
Rexulti sales fell short of expectations, while the company lifted its 2026 outlook with minimal changes to analyst forecasts.
Lundbeck announced its orexin‑2 selective agonist entered Phase Ib trials for daytime hypersomnolence.